| abstract |
An immunogenic composition comprising a. a directed adjuvant comprising at least one anti-CD32 radical bound to a TLR9 ligand and a first peptide alpha helix, wherein (i) said anti-CD32 radical is a protein, polypeptide or peptide that specifically binds to CD32; and (ii) said TLR9 ligand is a TLR9 agonist selected from the group consisting of CpG oligodeoxynucleotides of class A, B and C; and b. a gastrin-17 peptide immunogen attached to a second peptide alpha helix coiled to the first alpha helix, whose peptide immunogen is one of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment of the same comprising the amino acid sequence of SEQ ID 2, or at least the 4 Final amino acids of SEQ ID 2; (ii) a rhesus or murine monkey gastrin-17 peptide; and / or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. |